Introduction to EID2, A Potential Drug Target (G163126)

Target Name: EID2

NCBI ID: G163126

EID2

Introduction to EID2, A Potential Drug Target
EID2, also known as E3 ubiquitin-protein ligase HERC2, is a protein that plays a crucial role as a drug target in various diseases. It serves as an E3 ubiquitin ligase, which is responsible for transferring ubiquitin molecules to specific cellular proteins, thereby regulating their degradation or signaling functions. EID2 has gained significant attention in recent years due to its involvement in several important cellular processes, making it an attractive target for drug development and as a potential biomarker for disease diagnosis and prognosis.

The Role of EID2 in Protein Degradation
EID2 is involved in the regulation of protein degradation through the ubiquitin-proteasome system (UPS). This system plays a critical role in maintaining protein homeostasis and removing damaged or misfolded proteins. EID2 functions by recognizing specific target proteins and catalyzing the attachment of ubiquitin molecules to their lysine residues. This ubiquitination process acts as a signaling mechanism, which labels the protein for degradation by the proteasome. By targeting specific proteins for degradation, EID2 helps in maintaining cellular equilibrium and preventing the accumulation of harmful proteins.

EID2 and Cancer
One area where EID2 has shown great potential as a drug target is in cancer therapy. Dysregulation of protein degradation pathways is often observed in cancer cells, leading to the accumulation of oncogenic proteins and contributing to tumor growth and progression. EID2 plays a vital role in this context by selectively targeting cancer-specific proteins for degradation. Studies have shown that inhibiting EID2 activity can lead to the accumulation of these proteins, thereby triggering apoptosis and inhibiting cancer cell proliferation. Therefore, developing inhibitors that specifically target EID2 could provide a promising strategy for cancer treatment.

EID2 as a Biomarker for Neurodegenerative Diseases
In addition to its role as a drug target, EID2 also holds potential as a biomarker for neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's and Parkinson's, are characterized by the accumulation of abnormal protein aggregates in the brain, leading to neuronal dysfunction and death. EID2 has been found to be involved in the regulation of protein aggregates, and its dysfunction has been linked to the pathogenesis of these diseases. Consequently, the measurement of EID2 levels in biological fluids, such as cerebrospinal fluid or blood, could serve as a diagnostic biomarker for the early detection and monitoring of neurodegenerative diseases.

Therapeutic Opportunities and Challenges
With the identification of EID2 as a potential drug target and biomarker, there are several therapeutic opportunities and challenges associated with its manipulation. Developing small molecules or antibodies that selectively modulate EID2 activity could offer new avenues for drug discovery and treatment of various diseases. However, the design and development of such molecules need to overcome the challenges associated with selectively targeting EID2 without affecting other essential cellular processes. Additionally, the validation of EID2 as a biomarker requires extensive clinical studies to establish its specificity and sensitivity in different disease conditions.

Conclusion
EID2, an E3 ubiquitin-protein ligase, has emerged as an important target for drug development and a potential biomarker for disease diagnosis and prognosis. Its involvement in protein degradation pathways and its dysregulation in various diseases make it an attractive candidate for therapeutic intervention. In cancer, specifically inhibiting EID2 activity could lead to the selective degradation of oncogenic proteins, offering a novel approach to cancer treatment. Moreover, the measurement of EID2 levels in body fluids could provide valuable insights into the progression of neurodegenerative diseases. However, further research and clinical validation are required to fully understand the therapeutic potential and diagnostic utility of EID2.

Protein Name: EP300 Interacting Inhibitor Of Differentiation 2

Functions: Interacts with EP300 and acts as a repressor of MYOD-dependent transcription and muscle differentiation. Inhibits EP300 histone acetyltransferase activity. Acts as a repressor of TGFB/SMAD transcriptional responses. May act as a repressor of the TGFB/SMAD3-dependent signaling by selectively blocking formation of TGFB-induced SMAD3-SMAD4 complex

The "EID2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EID2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets